Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic

Pyoeng-Gyun CHOE; Yuri KIM; Euijin CHANG; Chang-Kyung KANG; Nam-Joong KIM; Nam-Hyuk CHO; Wan-Beom PARK; Myoung-don OH.
Journal of Korean Medical Science ; : e67-2022.
Artículo en Inglés | WPRIM | ID: wpr-925897

Documentos relacionados

  1. Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic.
  2. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
  3. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
  4. SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression.
  5. Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19.
  6. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  7. Genes involved in the limited spread of SARS-CoV-2 in the lower respiratory airways of hamsters may be associated with adaptive evolution.
  8. Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection.
  9. Impact of Vaccination, Prior Infection, and Therapy on Omicron Infection and Mortality.
  10. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.